Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27782514 | 0.88 | PTPN1 (0.42) | SMN1; SMN2LMNAALDH1A1MAPK1NPC1 | |
| SCHEMBL27910335 | 0.84 | KDM5A (0.40) | SMN1; SMN2LMNAALDH1A1MAPK1KMO | |
| SCHEMBL28350740 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAALDH1A1MAPK1KMO | |
| SCHEMBL8660548 | 0.80 | LMNA (0.42) | SMN1; SMN2LMNAALDH1A1KMOMAPT | |
| SCHEMBL9139692 | 0.79 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1METAP2GABRPGABRD | |
| SCHEMBL1997421 | 0.79 | METAP2 (0.42) | SMN1; SMN2ALDH1A1KMOMETAP2GABRP | |
| SCHEMBL7259052 | 0.79 | KDM4E (0.40) | SMN1; SMN2ALDH1A1MAPTMETAP2GABRP | |
| SCHEMBL10694897 | 0.79 | KDM4E (0.47) | ALDH1A1MAPTL3MBTL1METAP2GABRP | |
| SCHEMBL27775355 | 0.79 | GABRP (0.40) | SMN1; SMN2ALDH1A1MAPTMETAP2GABRP | |
| SCHEMBL18795788 | 0.78 | METAP2 (0.35) | SMN1; SMN2ALDH1A1MAPTMETAP2GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-07-16 | — | — | US | disclosed |
| US-20200216434-A1 | BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-07-09 | — | — | US | disclosed |
| EP-3638664-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | European Molecular Biology Laboratory (DE) | 2020-04-22 | — | — | EP | disclosed |
| EP-3638662-A1 | BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | European Molecular Biology Laboratory (DE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018229194-A1 | BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2018-12-20 | — | — | WO | disclosed |
| WO-2018229193-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2018-12-20 | — | — | WO | disclosed |
| EP-2903965-B1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | ORION CORP (FI) | 2017-03-01 | — | — | EP | disclosed |
| US-9567325-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-02-14 | — | — | US | disclosed |
| US-9533952-B2 | N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists | ORION CORPORATION (FI) | 2017-01-03 | — | — | US | disclosed |
| US-20150376130-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | Orlon Corporation (FI) | 2015-12-31 | — | — | US | disclosed |
| EP-1120410-A1 | Nicotinic acid esters useful as CNS agents and having affinity for 5-HT receptors | Pharmacia AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| EP-0636127-B1 | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN INC (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6090826-A | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN SALES, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5750693-A | THIOCHROMANYL OR CHROMANYL COMPOUNDS AS ANTICARCINOGINIC AGENTS, SKIN DISORDERS AND ATHEROSCLEROSIS | ALLERGAN (US) | 1998-05-12 | — | — | US | disclosed |
| US-5663347-A | REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION; TREATMENT OF SKIN DISORDERS; ANTICARCINOGNIC AGENTS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
| US-5658910-A | TREATING MENTAL DISORDERS | PHARMACIA AB (SE) | 1997-08-19 | — | — | US | disclosed |
| US-5468879-A | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN, INC. (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0673368-A1 | NOVEL NICOTINIC ACID ESTERS | Pharmacia & Upjohn Aktiebolag (SE) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994000434-A1 | NOVEL NICOTINIC ACID ESTERS | KABI PHARMACIA AB (SE) | 1994-01-06 | — | — | WO | disclosed |
| US-5264578-A | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN, INC. (US) | 1993-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376130-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | SMN1; SMN2 2620/4885LMNA 1569/4885ALDH1A1 1295/4885 |
| US-20200216434-A1 | BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | NR0B1, NR4A3, NR0B2 | SMN1; SMN2 2277/4885LMNA 1479/4885ALDH1A1 2233/4885 |
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | SUCNR1, CBR1, CYP2A13 | SMN1; SMN2 1329/4885LMNA 2009/4885ALDH1A1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.